Cor Vasa 2007, 49(4):134-137 | DOI: 10.33678/cor.2007.051

Genetic determination of the prognosis in survivors of acute coronary syndromes. Study design and rationale for a multicenter study

Jan Pi»ha1, Jaroslav A. Hubáček1, Rudolf Poledne1, Vladimír Staněk2, Michael Aschermann3, Marie Gebauerová2, Petr Hájek4, Petr Niederle5, Martin Pěnička6, Josef Veselka4
1 Laboratory for Atherosclerosis Research
2 Clinic of Cardiology, Institute for Clinical and Experimental Medicine
3 General Teaching Hospital, Second Department of Internal Medicine and Charles University Medical Faculty 1
4 CardioVascular Center, Department of Cardiology, Motol University Hospital
5 Department of Cardiology, Na Homolce Hospital
6 Cardiocenter, Department of Cardiology, Královské Vinohrady University Hospital and Third Medical Faculty, Prague, Czech Republic

Powerful predictors have already been established for clinical complications ensuing from acute coronary events. Despite this, substantial differences exist between patients at apparently similar risk. Amongst the most frequently discussed newer predictors of clinical events are genes and their interactions. Identification of disadvantageous variants of candidate genes could help to detect the patients suitable for more consistent follow-up and the best possible treatment. The two main aims of this study are, first, identification of the particular alleles and genotypes responsible for acute coronary events in a large population of Czech patients in a cross-sectional study and, second, determination of the effect of these alleles on clinical outcomes in a prospective study. A total of 2,500 patients with acute coronary syndromes from 5 coronary care units based in Prague are to be recruited. A control group is to comprise a representative 1% population sample of 2,600 individuals. The polymorphisms of the following most frequently discussed single genes are to be studied: the connexin 37 gene, stromelysin-1 gene, plasminogen activator-inhibitor type 1 gene, and the lymphotoxin-alpha gene.

Keywords: Acute coronary syndrome; Genetic polymorphism; Population-based study

Published: April 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pi»ha J, Hubáček JA, Poledne R, Staněk V, Aschermann M, Gebauerová M, et al.. Genetic determination of the prognosis in survivors of acute coronary syndromes. Study design and rationale for a multicenter study. Cor Vasa. 2007;49(4):134-137. doi: 10.33678/cor.2007.051.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Zdravkovic S, Wienke A, Pedersen NL, Marenberg ME, Yashin AI, De Faire U. Heritability of death from coronary heart disease: a 36-year follow-up of 20 966 Swedish twins. J Intern Med 2002;252:247-54. Go to original source... Go to PubMed...
    2. Marienberg ME, Risch N, Bergman LF, Floderus B, de Faire U. Genetic susceptibility to death from coronary heart disease in a study of twins. New Engl J Med 1994; 330:1041-6. Go to original source... Go to PubMed...
    3. Morange PE, Henry M, Frere C, Juhan-Vague I; HIFMECH study group. Thr325IIe polymorphism of the TAFI gene does not influence the risk of myocardial infarction. Blood 2002;99:1878-9. Go to original source... Go to PubMed...
    4. Liu PY, Li YH, Chan SH, et al. Genotype-phenotype association of matrix metalloproteinase-3 polymorphism and its synergistic effect with smoking on the occurrence of acute coronary syndrome. Am J Cardiol 2006;98:1012-7. Go to original source... Go to PubMed...
    5. Mangino M, Braund P, Singh R, et al. LGALS2 functional variant rs7291467 is not associated with susceptibility to myocardial infarction in Caucasians. Atherosclerosis 2006 [Epub ahead of print]. Go to original source... Go to PubMed...
    6. Lanfear DE, Jones PG, Marsh S, Cresci S, McLeod HL, Spertus JA. Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome. JAMA 2005;294: 1526-33. Go to original source... Go to PubMed...
    7. Shiffman D, Rowland CM, Louie JZ, et al. Gene variants of VAMP8 and HNRPUL1 are associated with early-onset myocardial infarction. Arterioscler Thromb Vasc Biol 2006;26:1613-8. Go to original source... Go to PubMed...
    8. Winkelmann BR, Marz W, Boehm BO, et al. Rationale and design of the LURIC study-a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease. Pharmacogen 2001;2:S1-S73. Go to original source... Go to PubMed...
    9. Clarke R, Xu P, Bennett D, et al. International Study of Infarct Survival (ISIS) Collaborators Lymphotoxin-alpha gene and risk of myocardial infarction in 6,928 cases and 2,712 controls in the ISIS case-control study. PLoS Genet 2006;2:e107. Go to original source... Go to PubMed...
    10. Yamada Y, Izawa H, Ichihara S, et al. Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. New Engl J Med 2002;347:1916-23. Go to original source... Go to PubMed...
    11. Ozaki K, Ohnishi Y, Iida A, et al. Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction. Nat Genet 2002; 32:650-4. Go to original source... Go to PubMed...
    12. Hubáček JA, Poledne R. Apolipoprotein E and its role in lipid metabolism, cardiovascular disease and Alzheimer disease. Prakt Lék 1998;78:162-5.
    13. Widimsky P, Budesinsky T, Vorac D, et al. 'PRAGUE' Study Group Investigators. Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction. Final results of the randomized national multicenter trial-PRAGUE-2. Eur Heart J 2003; 24:94-104. Go to original source... Go to PubMed...
    14. Stanek V, Gebauerová M, Horák J, et al. Change in the fate of middle-aged men with acute myocardial infarction. Cor Vasa 2004;46:319-25.
    15. Day N, Humphries SE. Electrophoresis for genotyping: microtiter array diagonal gel electrophoresis on horizontal polyacrylamide gels, hydrolink, or agarose. Anal Biochem 1994;222:389-95. Go to original source... Go to PubMed...
    16. Hubáček JA. PCR - polymerase chain reaction. Principles and applications in research and medical practice. Čas Lék čes 1996;135:611-3.
    17. Wong CW, Christen T, Roth I, et al. Connexin 37 protects against atherosclerosis by regulating monocyte adhesion. Nat Med 2006;12:950-4. Go to original source... Go to PubMed...
    18. Wong CW, Christen T, Pfenniger A, James RW, Kwak BR. Do allelic variants of the connexin37 1019 gene polymorphism differentially predict for coronary artery disease and myocardial infarction? Atherosclerosis 2006;[Epub ahead of print]. Go to original source... Go to PubMed...
    19. Mizuno H, Sato H, Sakata Y, et al. Osaka Acute Coronary Insufficiency Study (OACIS) Group. Impact of atherosclerosis-related gene polymorphisms on mortality and recurrent events after myocardial infarction. Atherosclerosis 2006;185:400-5. Go to original source... Go to PubMed...
    20. Liu PY, Li YH, Chan SH, et al. Genotype-phenotype association of matrix metallo-proteinase-3 polymorphism and its synergistic effect with smoking on the occurrence of acute coronary syndrome. Am J Cardiol 2006;98:1012-7. Go to original source... Go to PubMed...
    21. Ding J, Nicklas BJ, Fallin MD, et al. Plasminogen activator inhibitor type 1 gene polymorphisms and haplotypes are associated with plasma plasminogen activator inhibitor type 1 levels but not with myocardial infarction or stroke. Am Heart J 2006;152:1109-15. Go to original source... Go to PubMed...

    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes